High response rates for T‐VEC in early metastatic melanoma (stage IIIB/C‐IVM1a)

@article{Franke2019HighRR,
  title={High response rates for T‐VEC in early metastatic melanoma (stage IIIB/C‐IVM1a)},
  author={V. Franke and D. Berger and W. Klop and B. van der Hiel and B. A. Van de Wiel and S. ter Meulen and M. Wouters and W. V. van Houdt and A. V. van Akkooi},
  journal={International Journal of Cancer},
  year={2019},
  volume={145}
}
Talimogene laherparepvec (T‐VEC) is a modified herpes simplex virus, type 1 (HSV‐1), which can be administered intralesionally in patients with stage IIIB/C‐IVM1a unresectable melanoma (EMA label). The phase 3 OPTiM registration study showed an overall response rate (ORR) of 26%. Since December 2016, 48 eligible patients started treatment at the Netherlands Cancer Institute. We included 26 patients in this study with a follow up time ≥6 months, reporting Overall Response Rate (ORR), Disease… Expand
T-VEC for stage IIIB-IVM1a melanoma achieves high rates of complete and durable responses and is associated with tumor load: a clinical prediction model
TLDR
The prediction model shows that use of T-VEC in patients with less tumor burden is associated with better outcomes, suggesting use earlier in the course of the disease. Expand
A Retrospective Chart Review Study of Real-World Use of Talimogene Laherparepvec in Unresectable Stage IIIB–IVM1a Melanoma in Four European Countries
TLDR
The differences between European countries were apparent, with physicians in the Netherlands using T-VEC in patients with earlier advanced disease stage and in the first-line setting compared with other countries. Expand
Efficacy of Talimogene Laherparepvec (T-VEC) Therapy in Patients with In-Transit Melanoma Metastasis Decreases with Increasing Lesion Size
TLDR
T-V EC lesion diameter was persistently associated with clinical response and is a readily assessed predictor of successful T-VEC therapy, corroborates recent data suggesting response rates to T- VEC may be higher than reported in clinical trials. Expand
Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany
TLDR
This real-life cohort treatment with T-VEC showed a high ORR and a large number of durable CRs, similar to previous studies of the therapy in patients with distant metastases. Expand
Talimogene laherparepvec treatment to overcome loco-regional acquired resistance to immune checkpoint blockade in tumor stage IIIB–IV M1c melanoma patients
TLDR
The usage of T-VEC is described in stage IVM1b-M1c melanoma patients, who achieved complete remission or stable disease upon systemic treatment but suffered from a loco-regional recurrence, and represents an effective and tolerable treatment option. Expand
Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB–IVM1c melanoma
TLDR
It is indicated that T-VEC induces systemic immune activity and alters the tumor microenvironment in a way that will likely enhance the effects of other immunotherapy agents in combination therapy. Expand
Observational study of talimogene laherparepvec use for melanoma in clinical practice in the United States (COSMUS-1)
TLDR
T-VEC was well tolerated and showed clinical utility as an intralesional treatment for unresectable cutaneous, subcutaneous and nodal melanoma in US clinical practice. Expand
Complete response to talimogene laherparepvec in a primary acral lentiginous melanoma.
TLDR
This is the first case ever reported in which a primary ALM is (successfully) treated with T-VEC, and a histopathologically confirmed complete response was achieved. Expand
Real-World Experience of Talimogene Laherparepvec (T-VEC) in Old and Oldest-Old Patients with Melanoma: A Retrospective Single Center Study
TLDR
This study provides further evidence for an effective use of T-VEC in old and oldest-old patients as the low rate of adverse events seems to be favorable compared to other systemic melanoma therapies and duration of treatment was short and therapy costs were lower than would have been expected from clinical trial data. Expand
Retreatment with talimogene laherparepvec for advanced melanoma.
TLDR
Intralesional T-VEC may be effective and well-tolerated in patients who have completed prior T.VEC therapy in patients with stage IIIB-IV melanoma after experiencing recurrence of locoregional disease or prior treatment-limiting toxicity. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 15 REFERENCES
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
TLDR
T-VEC is the first oncolytic immunotherapy to demonstrate therapeutic benefit against melanoma in a phase III clinical trial and represents a novel potential therapy for patients with metastatic melanoma. Expand
Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study
TLDR
A post hoc analysis of the systemic effects of talimogene laherparepvec in injected lesions and two types of uninjected lesions—non-visceral lesions and visceral lesions shows support of a delayed regional and systemic anti-tumor immune response to talimogen lahersparePvec. Expand
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
TLDR
Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation in a phase 3 randomized clinical trial. Expand
Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial
TLDR
The subgroup of patients with stage IIIB, IIIC and IVM1a melanoma derived greater benefit in DRR and ORR from talimogene laherparepvec compared with GM-CSF, and the overall response rate (ORR) was well tolerated. Expand
Improved survival with ipilimumab in patients with metastatic melanoma.
TLDR
Ipilimumab, with or without a gp100 peptide vaccine, as compared with gp100 alone, improved overall survival in patients with previously treated metastatic melanoma. Expand
OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma.
TLDR
A prospective, randomized Phase III clinical trial in patients with unresectable Stage IIIb or c and Stage IV melanoma has been initiated and the rationale, study design, end points and future development of the Oncovex(GM-CSF) Pivotal Trial in Melanoma (OPTIM) trial are discussed in this article. Expand
Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors
TLDR
Talimogene laherparepvec was active in patients with advanced melanoma with disease progression following multiple previous systemic therapies; no new safety signals were identified. Expand
Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma.
TLDR
The 26% response rate, with durability in both injected and uninjected lesions including visceral sites, together with the survival rates, are evidence of systemic effectiveness, combined with a limited toxicity profile, warrants additional evaluation of JS1/34.5-/47-/GM-CSF in metastatic melanoma. Expand
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy
TLDR
The findings suggest that oncolytic virotherapy may improve the efficacy of anti-PD-1 therapy by changing the tumor microenvironment. Expand
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.
  • J. Chesney, I. Puzanov, +15 authors H. Kaufman
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2018
TLDR
The study met its primary end point; the objective response rate was significantly higher with talimogene laherparepvec plus ipilimumab versus ipilitationab alone, indicating that the combination has greater antitumor activity without additional safety concerns versus ipILimumab. Expand
...
1
2
...